logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
delete
arrow
返回
R

Raja Atreya

deutsches zentrum immuntherapie

67H指数
659论文数
1.7W被引数
收录论文 239
发表时间
logo
Feasibility and expert evaluation of a medical large language model in an interdisciplinary clinical board一种医学大型语言模型在跨学科临床委员会中的可行性与专家评估
errScientific Reports
IF3.9
err2026-10-02
err0
errOAAI
errMoritz Ronicke; Lukas Sollfrank; Ioannis Sagonas; Raja Atreya; Ricardo Grieshaber-Bouyer; André Hoerning; André Jefremow; Isabel Kowalski; Tobias Krickau; Jennifer Lermer; Norbert Meidenbauer; Jürgen Rech; Veit Rothhammer; Gunnar Schley; Wiebke Sondermann; Michel Sticherling
err分享
err收藏
Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy与BCMA car-t细胞治疗相关的小肠结肠炎中粘膜car-t细胞的持久性和炎症重塑
errNature Medicine
IF50
err2026-09-23
err0
PREAI
errNikhit Kethidi; Saumya Pothukuchi; Adolfo Aleman; Daniel Charytonowicz; Christina Kuhn; Thomas Wong; Jennifer Claytor; Pablo Canales-Herrerias; Samane Khoshbakht; Akanksha Acharya; Michael Tankelevich; Tin Htwe Thin; Divya Jha; Matthias Ceulemans; Alexandra E. Livanos; Catherine Le Berre; Zachary M. Avigan; Luise Fischer; Jacqueline E. Birkness-Gartman; Joanna Melia; Yimei Jin; Rachel Chen; Isha Parikh; Meenakshi Mehrotra; Erika Patel; Shriya Desai; Sidorela Reci; Kedwin Ventura; Rudra Prasad Dutta; Benjamin Gordon; Rachel Brody; Charlotte Cunningham-Rundles; Zhihong Chen; Seunghee Kim-Schulze; Parambir S. Dulai; Shruti Naik; Jane Houldsworth; Maximilian Merz; Randy S. Longman; Ivan Zanoni; Jeremiah Faith; Jean-Frederic Colombel; Britta Siegmund; Raja Atreya; Markus F. Neurath; Shambavi Richard; Sundar Jagannath; Jerome C. Martin; Eric Meffre; Mayte Suarez-Farinas; David Muniz Pedrogo; Alexandros D. Polydorides; Samir Parekh; Saurabh Mehandru
err分享
err收藏
Pharmacokinetics of IL-23p19 Inhibitors: A Systematic Review Across Immune-Mediated Inflammatory DiseasesIL-23p19抑制剂的药代动力学：免疫介导性炎症疾病领域的系统综述
errClinical Pharmacokinetics
IF4
err2026-08-22
err0
errOAAI
errIlse A. Pool; Alise D. E. de Groot; Ron J. Keizer; Marla C. Dubinsky; Joana Torres; Raja Atreya; Paul Malik; Erwin Dreesen; Gerard Dijkstra; Henkjan J. Verkade; Paola Mian; Arno R. Bourgonje
err分享
err收藏
Engineering immune cell therapies for inflammatory bowel disease: from stem cells to CAR T cells利用免疫细胞疗法治疗炎症性肠病：从干细胞到CAR-T细胞
errNature Reviews Gastroenterology & Hepatology
IF51
err2026-06-30
err0
PREAI
errMarkus F. Neurath; Raja Atreya; Jean-Frederic Colombel; Saurabh Mehandru
err分享
err收藏
A decade of clinical data with vedolizumab: the past, present, and future维得利珠单抗十年临床数据：过去、现在与未来
errTherapeutic Advances in Gastroenterology
IF3.4
err2026-05-25
err0
PREAI
errVipul Jairath; Alessandro Armuzzi; Christian Agboton; Brian Bressler; Silvio Danese; Parambir S. Dulai; Marlies Meyer; Itzel Romo Bautista; Raja Atreya; Brian G. Feagan
err分享
err收藏
Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative Colitis基于先前高级别治疗失败的活动中度至重度溃疡性结肠炎患者中米里克珠单抗对临床和内镜结局的影响
errUnited European Gastroenterology Journal
IF6.7
err2026-05-01
err0
errOAAI
errHart, Ailsa; Navabi, Seyedehsan; D'Haens, Geert; Matsuoka, Katsuyoshi; Martin-Arranz, Maria Dolores; Atreya, Raja; Samaan, Karen Hamrick; Dhesi, Endip; Redondo, Isabel; Zhu, Baojin; Paulissen, Jerome; Zaremba-Pechmann, Liliana; Baygani, Simin; Limdi, Jimmy; Laharie, David; Danese, Silvio
err分享
err收藏
Authors' response to letter to editor-silencing GATA3: DNAzymes enter the therapeutic landscape of ulcerative colitis作者对编辑来信的回应：沉默GATA3：DNA酶进入溃疡性结肠炎的治疗领域
errInflammatory Bowel Diseases
IF4.3
err2026-05-01
err0
PREAI
errAtreya, Raja; Neurath, Markus F.
err分享
err收藏
Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial靶向转录因子GATA3的DNAzyme制剂SB012在中等至重度活动性溃疡性结肠炎患者中的治疗：一项多中心、随机、安慰剂对照的2a期诱导试验
errInflammatory Bowel Diseases
IF4.3
err2026-05-01
err0
PREAI
errAtreya, Raja; Kuhbacher, Tanja; Vieth, Michael; Jefremow, Andre; Hirschmann, Simon; Waldner, Maximilian J.; Fischer, Sarah; Vetter, Marcel; Drvarov, Oliver; Weigmann, Benno; Meyer, Michael; Muhl, Tanja; Homburg, Ursula; Sarigiannis, Georgios; Garn, Holger; Renz, Harald; Neurath, Markus F.
err分享
err收藏
Efficacy and health-related quality of life associated with second-line vedolizumab after first-line treatment with one anti-TNF in patients with ulcerative colitis: a meta-analysis of the GEMINI-1 and VISIBLE-1 trials溃疡性结肠炎患者经一种抗-TNF作为一线治疗后，接受二线 vedolizumab 治疗的疗效与健康相关生活质量：GEMINI-1 和 VISIBLE-1 试验的荟萃分析
errTherapeutic Advances in Gastroenterology
IF3.4
err2026-03-23
err0
errOAAI
errRaja Atreya; Julien Kirchgesner; Zoe Cheah; Patricia Biedermann; Lytske Bakker; Marlies Meyer; Tim Raine
err分享
err收藏
Successful treatment of severe retroauricular pyoderma gangrenosum with upadacitinib in a patient with Crohn’s disease and a history of cerebral venous sinus thrombosis一名患有克罗恩病且有过脑静脉窦血栓病史的患者，采用乌帕替尼成功治疗严重耳后坏疽性脓皮病。
errTherapeutic Advances in Gastroenterology
IF3.4
err2026-02-22
err0
errOAAI
errFotios Fousekis; Moritz Ronicke; Lukas Sollfrank; Jürgen Rech; Carola Berking; Markus F. Neurath; Michael Sticherling; Raja Atreya
err分享
err收藏
Definitions, diagnosis, management, and outcomes of upper gastrointestinal Crohn's disease: an international, expert RAND/UCLA appropriateness study定义、诊断、管理及上消化道克罗恩病的结局：一项国际专家RAND/UCLA适宜性研究
errThe Lancet Gastroenterology & Hepatology
IF38.6
err2026-01-08
err0
PREAI
errNathaniel A Cohen; Dominik Bettenworth; Neta Sror; Raneem Khedraki; Qijun Yang; Maria T Abreu; Raja Atreya; Badr Al-Bawardy; Susan J Connor; Geert D'Haens; Iris Dotan; Axel Dignass; Sara El Ouali; Brian Feagan; Roger Feakins; Richard Gearry; Ilyssa O Gordon; Charlotte R H Hedin; Cristian Hernandez-Rocha; Taku Kobayashi
err分享
err收藏
GPR15-mediated trafficking of antibody-secreting cells in Inflammatory Bowel DiseaseGPR15介导的抗体分泌细胞在炎症性肠病中的迁移
errJournal of Crohns & Colitis
IF8.7
err2026-01-01
err0
PREAI
errSchramm, S.; Dedden, M.; Atreya, R.; Zundler, S.
err分享
err收藏
Obefazimod enhances miR-124 expression in blood and colon tissue and reduces the key inflammatory cytokines IL-17A and IL-6 in serum of patients with moderate-to-severely active ulcerative colitis: results from the Phase 3 ABTECT induction trials奥贝法西莫德增强溃疡性结肠炎患者血液和结肠组织中miR-124的表达，并降低血清中的关键炎症细胞因子IL-17A和IL-6：来自第3期ABTECT诱导试验的结果
errJournal of Crohns & Colitis
IF8.7
err2026-01-01
err0
PREAI
errSiegmund, B.; Danese, S.; Dubinsky, M. C.; Atreya, R.; Abecassis-Borgus, A.; Apolit, C.; Sandri, J.; Belda, C.; Amin, P.; Santo, J.; Mosig, R.; Jacobstein, D.; Cataldi, F.; Rabbat, C.; Howaldt, S.; Verstockt, B.; D'Haens, G.; Dulai, P.
err分享
err收藏
Pooled analysis of efficacy and safety of once-daily oral obefazimod in European patients from the ABTECT Phase 3, double-blind, placebo-controlled induction trials欧洲患者中每日一次口服奥贝非米德在ABTECT III期、双盲、安慰剂对照诱导试验中的疗效和安全性的合并分析
errJournal of Crohns & Colitis
IF8.7
err2026-01-01
err0
PREAI
errScaldaferri, F.; Seidler, U.; Treton, X.; D'Amico, F.; Armuzzi, A.; Howaldt, S.; Heeren, S.; Atreya, R.; Baert, F. J.; Tilg, H.; Cataldi, F.; Jacobstein, D.; Rabbat, C.; Shan, K.; Cicala, M.
err分享
err收藏
Durable Efficacy of Risankizumab Through Week 148 in Patients With Moderate-to-Severe Crohn's Disease: A Post Hoc Analysis of Part 2 of the SEQUENCE Study中重度克罗恩病患者中利斯克珠单抗至第148周的持久疗效：SEQUENCE研究第2部分的事后分析
errJournal of Crohns & Colitis
IF8.7
err2026-01-01
err0
PREAI
errAtreya, R.; Lindsay, J.; Ferrante, M.; Siegmund, B.; Cao, Q.; Van Haaren, S.; Crowley, J.; Anschutz, T.; Garrison, A.; Huang, X.; Dubinsky, M. C.
err分享
err收藏
Early symptomatic improvement with obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from the ABTECT-1 and ABTECT-2 Phase 3, double-blind, placebo-controlled induction trials奥贝非齐模德治疗中重度活动性溃疡性结肠炎患者的早期症状改善：ABTECT-1和ABTECT-2两项III期、双盲、安慰剂对照诱导试验的合并结果
errJournal of Crohns & Colitis
IF8.7
err2026-01-01
err0
PREAI
errArmuzzi, A.; Atreya, R.; Sparrow, M. P.; Markovic, S.; Le Berre, C.; Hlavaty, T.; Treton, X.; Cataldi, F.; Jacobstein, D.; Rabbat, C.; Shan, K.; Dubinsky, M. C.
err分享
err收藏
Analysis of Long-Term Safety and Efficacy of Risankizumab in Patients With Moderate-to-Severe Crohn's Disease: 3-Year Results From the SEQUENCE Study分析中重度克罗恩病患者中 risankizumab 的长期安全性和有效性：SEQUENCE 研究的3年结果
errJournal of Crohns & Colitis
IF8.7
err2026-01-01
err0
PREAI
errPeyrin-Biroulet, L.; Atreya, R.; Danese, S.; Lindsay, J.; Chapman, J. C.; Anschutz, T.; Huang, X.; Zambrano, J.; Aponte, F.; Joshi, N.; Cross, R.
err分享
err收藏
Impact of prior inadequate response to advanced therapies on early symptomatic improvement with obefazimod induction in moderately to severely active ulcerative colitis: results from the two Phase 3 placebo-controlled ABTECT induction trials既往对先进疗法反应不足对奥贝芬尼诱导早期症状改善的影响：中度至重度活动性溃疡性结肠炎的ABTECT诱导试验III期安慰剂对照试验结果
errJournal of Crohns & Colitis
IF8.7
err2026-01-01
err0
PREAI
errAtreya, R.; Sands, B. E.; Rubin, D. T.; Dubinsky, M. C.; Armuzzi, A.; Treton, X.; Cataldi, F.; Jacobstein, D.; Rabbat, C.; Shan, K.; Hlavaty, T.; Witek, R.; Dulai, P.; Danese, S.
err分享
err收藏
Impact of baseline body mass index (BMI) on efficacy of obefazimod in patients with moderately to severely active ulcerative colitis: results from the Phase 3 ABTECT induction trials基线体重指数(BMI)对中重度活动性溃疡性结肠炎患者奥贝芬米德疗效的影响：来自第3期ABTECT诱导试验的结果
errJournal of Crohns & Colitis
IF8.7
err2026-01-01
err0
PREAI
errRubin, D. T.; Dubinsky, M. C.; Scaldaferri, F.; Cataldi, F.; Jacobstein, D.; Rabbat, C.; Shan, K.; Ramos Junior, O.; Leoshyk, O.; De Sa Rolim, A.; Bouhnik, Y.; Atreya, R.
err分享
err收藏
Effectiveness of First- and Second-Line Advanced Therapy in Microscopic Colitis: A Real-World Cohort Study微小结肠炎中一线和二线先进疗法的有效性：一项真实世界队列研究
errJournal of Crohns & Colitis
IF8.7
err2026-01-01
err0
PREAI
errJefremow, A.; Fousekis, F.; Neurath, M. F.; Atreya, R.
err分享
err收藏

研究方向

暂时未获取到该数据
合作学者
合作期刊
W
William J. Sandborn
H 指数: 199 · 论文数: 2.1K
S
Stefan Schreiber
H 指数: 192 · 论文数: 1.9K
S
Séverine Vermeire
H 指数: 163 · 论文数: 2.4K
T
Tadamitsu Kishimoto
H 指数: 161 · 论文数: 852
G
Georg Schett
H 指数: 154 · 论文数: 1.7K
查看更多